ZTS (Zoetis) Other Long-Term Liabilities: $220 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZTS Zoetis Inc ZTS
69 GF Score
Price $75.84
GF Value $181.03
Valuation Significantly Undervalued
View Full Analysis

What is Zoetis Other Long-Term Liabilities?

Zoetis ZTS +3.13% 69 Other Long-Term Liabilities is $220 Mil as of Jun. 2026. GuruFocus rates ZTS with a GF Score™ of 69/100 and a GF Value™ of $181.03 (Significantly Undervalued).

Zoetis's other long-term liabilities for the quarter that ended in Jun. 2026 was $220 Mil.

Zoetis's quarterly other long-term liabilities declined from Dec. 2025 ($248 Mil) to Mar. 2026 ($219 Mil) but then increased from Mar. 2026 ($219 Mil) to Jun. 2026 ($220 Mil).

Zoetis's annual other long-term liabilities declined from Dec. 2023 ($237 Mil) to Dec. 2024 ($222 Mil) but then increased from Dec. 2024 ($222 Mil) to Dec. 2025 ($248 Mil).

Zoetis Other Long-Term Liabilities Related Terms

Zoetis Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Zoetis's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zoetis Other Long-Term Liabilities Chart

Zoetis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 239.00 217.00 237.00 222.00 248.00

Zoetis Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 274.00 264.00 248.00 219.00 220.00
ZTS
69GF Score
Zoetis Inc ZTS
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zoetis Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $220 Mil mean?
Zoetis (ZTS) has a Other Long-Term Liabilities of $220 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Zoetis and its competitors.
Is Zoetis' Other Long-Term Liabilities too high?
Zoetis' current Other Long-Term Liabilities is $220 Mil. Overall, Zoetis has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' Other Long-Term Liabilities compare to UTHR and VTRS?
Zoetis' Other Long-Term Liabilities of $220 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Zoetis and its competitors. Zoetis's current Other Long-Term Liabilities is $220 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is $181.03, compared to a current price of $75.84 — trading 58.1% below its estimated fair value. The current Other Long-Term Liabilities is $220 Mil. Zoetis' overall GF Score™ is 69/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Zoetis (ZTS), the current Other Long-Term Liabilities is $220 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zoetis (ZTS) Overvalued in 2026?

Based on GuruFocus' analysis, Zoetis stock appears to be undervalued. The current stock price of $75.84 is trading 58.1% below its estimated GF Value™ of $181.03. GuruFocus considers Zoetis to be Significantly Undervalued.

Key valuation signals for ZTS:

  • Other Long-Term Liabilities: $220 Mil
  • GF Value™: $181.03 vs. price of $75.84 (58.1% below fair value)
  • GF Score™: 69/100

No single metric tells the full story. See the ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zoetis Business Description

Address 10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
69GF Score

Get the complete analysis for ZTS

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$75.84
Price
$181.03
GF Value